1. Introduction {#sec1-jcm-09-02289}
===============

Chronic kidney disease (CKD) has a major public health impact all over the world, due to its systemic nature \[[@B1-jcm-09-02289]\] and the link with multiple risk factors \[[@B2-jcm-09-02289]\]. The risk of hospitalization and overall mortality increases with the decrease of the renal function and the increase in albuminuria, a sign of advanced renal damage typical of diabetics \[[@B3-jcm-09-02289]\]. While traditional risk factors (diabetes, hypertension, and hypercholesterolemia) contribute to the elevated cardiovascular risk at early CKD stages, inflammation, malnutrition, loss of body weight, muscular mass, and cachexia become more dominant during advanced stages and predict the mortality rate. In this "reverse epidemiology" context, low cholesterol levels determine the highest rate of cardiovascular morbidity and mortality \[[@B4-jcm-09-02289],[@B5-jcm-09-02289]\].

We have previously demonstrated that reduced high-density lipoprotein (HDL) cholesterol is the most remarkable lipid trait both in mild-to-moderate CKD patients \[[@B6-jcm-09-02289]\] and in hemodialysis patients \[[@B7-jcm-09-02289]\]. These initial observations were later confirmed in different populations \[[@B8-jcm-09-02289],[@B9-jcm-09-02289]\]. The uremic and inflammatory status are known to alter HDL lipid and protein composition; HDL from CKD patients present with reduced levels of apolipoprotein (apo)A-I, apoA-II, lecithin:cholesterol acyltransferase (LCAT) and paraoxonase, while pro-oxidant factors such as malondialdehyde, myeloperoxidase, and symmetric dimethylarginine are increased \[[@B7-jcm-09-02289],[@B10-jcm-09-02289],[@B11-jcm-09-02289],[@B12-jcm-09-02289]\]. CKD also affects the HDL subclass distribution; patients with CKD show an increased content of pre-beta HDL (preβ-HDL), owing to the reduced LCAT activity \[[@B7-jcm-09-02289]\]. All these modifications are believed to compromise some key HDL functions, such as the ability to promote cholesterol efflux \[[@B11-jcm-09-02289],[@B13-jcm-09-02289],[@B14-jcm-09-02289]\] and to promote endothelial nitric oxide production \[[@B12-jcm-09-02289]\] and also hamper the anti-inflammatory properties \[[@B15-jcm-09-02289]\]. Interestingly, the HDL profile observed in CKD patients mirrors the profile found in carriers of genetic LCAT deficiency \[[@B16-jcm-09-02289]\], possibly due to the acquired LCAT deficiency in CKD \[[@B7-jcm-09-02289]\]. Since the alterations in the lipid/lipoprotein profile in LCAT-deficient carriers are involved in the pathogenesis of renal disease \[[@B17-jcm-09-02289]\], which represents the first cause of morbidity and mortality in these subjects \[[@B18-jcm-09-02289]\], we test the hypothesis whether the reduced LCAT concentration in CKD contributes to the progression of renal damage. Moreover, we investigate whether low plasma LCAT concentration predicts CKD incidence and evolution in the general population. Finally, we test in vitro the impact of serum from subjects with low plasma LCAT concentration on oxidative stress in podocytes and tubular cells.

2. Materials and Methods {#sec2-jcm-09-02289}
========================

2.1. Study Cohorts {#sec2dot1-jcm-09-02289}
------------------

The study included two subsets of subjects selected from the PLIC study \[[@B6-jcm-09-02289],[@B19-jcm-09-02289],[@B20-jcm-09-02289],[@B21-jcm-09-02289]\], an epidemiological and prospective large survey of the general population of the northern area of Milan conducted at the Center for the Study of Atherosclerosis, Bassini Hospital (Cinisello Balsamo, Milan, Italy). The study was approved by the Ethic Committee of the University of Milano (SEFAP/Pr.0003).

The first cohort included 164 patients with CKD at the basal visit (the NefroPLIC cohort). This population has been previously described in detail \[[@B6-jcm-09-02289],[@B22-jcm-09-02289]\]. Briefly, CKD patients were enrolled through the outpatient ambulatory of the Unit of Nephrology and Dialysis of Bassini Hospital and followed-up for 84 months. Patients with any of the following conditions: inflammatory or infectious disorders, congenital or hereditary kidney diseases, previous dialysis (either peritoneal or hemodialysis), glomerulonephritis, cardiovascular events in the previous six months, microvascular complications (either as retinopathy, neuropathy, foot ulcers or gangrenes), previous major cardiac or vascular surgery, malignant neoplasms, and thyroid dysfunction were excluded from the study.

The second cohort consisted of 164 subjects randomly selected from the PLIC cohort with comparable age, relative prevalence of men and women, and with a median basal estimated glomerular filtration rate (eGFR) of 67.51 (60.01 as minimum and 122.03 as maximum) ml/min/1.73 m^2^.

All subjects provided a written informed consent and all procedures were performed in accordance with the Declaration of Helsinki.

2.2. Study Endpoints {#sec2dot2-jcm-09-02289}
--------------------

eGFR was estimated using the Cockroft--Gault formula. For the NefroPLIC cohort, the estimation of the Modification of Diet in Renal Disease equation was derived as well, in accordance with validated guidelines for CKD classification \[[@B23-jcm-09-02289]\]. For the basal characterization of the cohorts and to study correlation with clinical parameters, both groups were divided by LCAT concentration tertiles. To evaluate CKD progression, we considered dialysis entry (either peritoneal or hemodialysis) and/or basal creatinine level doubling as outcomes over time in the NefroPLIC cohort (up to seven years as maximum follow-up). In order to verify whether reduced LCAT concentration is a specific marker of the progression of renal disease, independently of other major co-morbidities, we also assessed the predictive value of reduced LCAT concentration for the following end-points occurring during follow-up: (1) all-cause mortality (from medical registries); (2) cardiovascular fatal or non-fatal events (either as atrial fibrillation, heart failure, stroke, transient ischemic attack, coronary-artery by-pass grafting, peripheral revascularization, amputations for gangrenes or microvascular complications); (3) composite outcome of dialysis entry and/or creatinine doubling + total mortality; (4) composite outcome of dialysis entry and/or creatinine doubling + cardiovascular fatal or non-fatal events; (5) composite outcome of dialysis entry and/or creatinine doubling + cardiovascular fatal or non-fatal events + all-cause mortality.

In parallel, to study the relation between the LCAT concentration and CKD incidence in the PLIC cohort, annual eGFR changes (annual variation of mL/min/1.73 m^2^) and eGFR decline below 60 mL/min were considered as end-points.

2.3. Biochemistry {#sec2dot3-jcm-09-02289}
-----------------

Blood and urine samples were collected after overnight fasting. Plasma, serum, and urine samples were stored at --80 °C until analysis. Lipid/apolipoprotein profile, liver enzymes, and cardio-metabolic markers were determined as previously described \[[@B6-jcm-09-02289]\]. Plasma LCAT concentration was determined by an immunoenzymatic assay developed in our laboratory \[[@B16-jcm-09-02289]\]. Pre-beta HDL content was determined by 2-D electrophoresis \[[@B24-jcm-09-02289]\].

First morning urine samples from three different days were collected, and the urinary albumin was measured using an immunoturbidimetric assay (Cobas Mira Plus Analyzer, Roche, France). The mean value of the three samples was calculated and normalized relative to the urinary levels of creatinine according to the guidelines of the American Diabetes Association. Urine samples were cultured at baseline to exclude infection as a possible etiology of proteinuria.

2.4. In Vitro Studies {#sec2dot4-jcm-09-02289}
---------------------

Experiments were performed using two different renal cell lines: immortalized human podocytes, maintained in Dulbecco′s Modified Eagle Medium (DMEM) containing 1g/L of glucose supplemented with 10% fetal bovine serum (FBS), 1% L-Glutamine, and 1% antibiotics; immortalized human tubular cells (HK2), cultured in DMEM enriched of nutrient mixture F-12 with 10% FBS, 1% L-Glutamine and 1% antibiotics.

To evaluate reactive oxygen species (ROS) production, both podocytes and tubular cells were starved in serum-free medium for 2 h and then incubated for 30 min with HEPES buffer containing 5 µM of carboxy-H2DCFDA (Molecular Probes, Invitrogen, Thermo Fisher, Rockford, IL, USA) before 1-h incubation with media containing 2% v/v of serum. Oxidation of the probe was detected by monitoring fluorescence at 517--527 nm. Data were normalized on total protein content measured with microBCA assay (Thermo Fisher Scientific, Rockford, IL, USA) on cell lysate.

Podocin gene expression was evaluated by quantitative real time polymerase chain reaction (RT-PCR). Briefly, RNA was isolated and transcribed to cDNA with the iScriptTM cDNA synthesis kit (BioRad, Hercules, CA, USA). Gene expression analysis was performed using Sso Advanced Universal SYBR Green Supermix (BioRad, Hercules, CA, USA) and the expression was normalized to a housekeeping gene (β-actin).

To test the effect of LCAT in determining the serum ability to promote ROS production, sera from 1st LCAT tertile subjects (*n* = 11) were incubated at 37 °C for 6 h with rhLCAT \[[@B24-jcm-09-02289]\] in the amount required to reach the final LCAT concentration of 6 μg/mL (identical to the average LCAT concentration in 3rd LCAT percentile subjects) or with the same volume of saline. Lipids and apolipoproteins were evaluated before and after incubation, as described above. After incubation, ROS production induced by sera was evaluated, as described above, in both cell lines. The effect of serum-free rhLCAT (6 μg/mL) was also tested.

2.5. Statistical Analyses {#sec2dot5-jcm-09-02289}
-------------------------

Statistical analyses were performed using SPSS^®^ v.23.0 for Windows^®^ (IBM Corporation^®^, Chicago IL, USA) software. A Shapiro--Wilk test was performed to verify the normal distribution of continuous variables. For normally distributed variables, the mean ± standard deviation (SD) is reported. The t-test was used for comparisons; for non-normally distributed variables, the median and inter-quartile range (IQR, as the range between the 25th and the 75th percentile around each median value) are reported, and the Mann-Whitney U nonparametric test was performed. For dichotomous variables, the chi squared test and relative risk (95% C.I., confidence interval) assessment were performed. Multiple stepwise Cox-regression models were used to verify in the nefroPLIC cohort the predictive value of reduced HDL-c or LCAT concentration for the studied outcomes (the forward selection of co-variates was applied with entry testing (set at 0.05) and removal testing (set at 0.1) based on the probability of the Wald statistic). Kaplan--Meier survival curves and log-rank tests compared CKD progression rates by LCAT concentration tertiles and they were compared by both univariate log-rank test and Cox-regression models setting the 3rd tertile (high LCAT concentration) as a reference vs. the 2nd and 1st tertile (lower LCAT concentration). A linear regression model was used to analyze the predictive value of reduced HDL-c or LCAT concentration (as continuous variables) for eGFR change over follow-up in the PLIC cohort. T-statistics were derived from linear regression models to estimate the size of the difference relative to the variation in HDL-c or LCAT concentration. eGFR changes across LCAT tertiles were compared, adjusting for co-variates, by the Analysis of Co-Variances (ANCOVA) model. Non-normally distributed variables were log-transformed when included in the multivariable models. The test of collinearity was implemented for each multivariable regression model to derive the Variation Inflation Factor (VIF) and excluded redundant covariates.

Box plots for data distributions, reporting mean values with 10th to 90th upper and lower bounds, were generated using GraphPad Prism 5^®^ for Windows^®^ (Graphpad Software Inc.^®^, La Jolla, CA, USA).

Results of the in vitro studies were compared by the Kruskall--Wallis test.

For all analyses, *p*-values \< 0.05 were considered statistically significant.

3. Results {#sec3-jcm-09-02289}
==========

3.1. Lower Plasma LCAT Concentration Predicts Disease Progression in Patients with Chronic Kidney Disease {#sec3dot1-jcm-09-02289}
---------------------------------------------------------------------------------------------------------

Among the 164 patients of the NefroPLIC cohort, 32 were identified as "fast CKD progression" patients (13 doubled basal creatinine and 19 entered dialysis during 84 months of follow-up). At the basal evaluation, these patients showed a metabolic profile similar to CKD patients who did not double basal creatinine and/or entered dialysis during follow-up ("Slow CKD progression") ([Table 1](#jcm-09-02289-t001){ref-type="table"}). Low HDL-c was confirmed as the unique lipid parameter reduced in patients experiencing faster CKD progression vs. those with slower progression (43.0 (14.72) vs 52.3 (14.8), *p* \< 0.001, [Table 1](#jcm-09-02289-t001){ref-type="table"}). Interestingly, also the plasma LCAT concentration was significantly reduced in patients experiencing faster CKD progression than in the slower progression group ([Figure 1](#jcm-09-02289-f001){ref-type="fig"}a) and, more importantly, was not correlated with HDL-c. Since we observed a poor statistical collinearity between the HDL-c and the LCAT concentration (Variation Inflation Factor (VIF) = 1.772 in a regression model setting LCAT as the independent variable and HDL-c as the dependent variable; VIF = 1.179 when setting HDL-c as the independent variable and LCAT as the dependent variable), we were thus prompted to investigate which was the most predictive parameter for faster CKD progression.

Cox regression model adjusted by age, gender, body mass index (BMI), systolic/diastolic blood pressure, anti-hypertensive treatments, glucose, glucose lowering treatments, albuminuria, total cholesterol, triglycerides, and lipid lowering treatments showed that reduced HDL-c is predictive of faster CKD progression (HR = 1.078 (1.016--1.143), *p* = 0.013). However, when also the LCAT concentration was included in the model, the reduction of HDL-c was of borderline statistical significance in predicting faster CKD progression (HR = 1.062 (0.999--1.129), *p* = 0.055) ([Table S1](#app1-jcm-09-02289){ref-type="app"}). Vice versa, 1 μg/mL reduction in LCAT concentration predicted by 0.78 with up to a 3.39 times higher risk of dialysis entry and/or creatinine doubling, even when HDL-c was included in the model among other co-variates (HR = 2.370 (1.278--4.396), *p* = 0.006) ([Table S2](#app1-jcm-09-02289){ref-type="app"}), suggesting that a reduced LCAT concentration independently predicts faster CKD progression beyond the contribution of low HDL-c.

It is worth noting that reduced LCAT concentration specifically predicted faster CKD progression and worse disease-related prognosis, as a 1 μg/mL reduction in LCAT concentration was predictive of an increased risk of a composite outcome of all-cause mortality and faster CKD progression (HR = 1.742 (1.060--2.864), *p* = 0.029), while it was not predictive for all-cause mortality alone (HR = 1.058 (0.487--2.297), *p* = 0.887) or for the occurrence of cardiovascular fatal or non-fatal events alone (HR = 0.622 (0.366--1.057), *p* = 0.079) ([Table S2](#app1-jcm-09-02289){ref-type="app"}).

In addition, to verify whether the predictive value of the reduced LCAT concentration was also independent of other metabolic and disease-related risk factors, we divided the cohort into tertiles of LCAT concentration, and no statistical differences in all the tested parameters was observed ([Table 2](#jcm-09-02289-t002){ref-type="table"}). Of note, patients with the lowest LCAT concentration (1st tertile) at the basal evaluation showed the highest event rate of dialysis entry and/or creatinine doubling during follow-up ([Figure 1](#jcm-09-02289-f001){ref-type="fig"}b), composite outcome of dialysis entry and/or creatinine doubling, and all-cause mortality ([Figure 1](#jcm-09-02289-f001){ref-type="fig"}e).

3.2. Lower Plasma LCAT Concentration Predicts Impairment of Kidney Function in General Population {#sec3dot2-jcm-09-02289}
-------------------------------------------------------------------------------------------------

To investigate if the LCAT concentration could predict the impairment of kidney function in the general population, we selected a subset of subjects with basal eGFR over 60 mL/min/1.73 m^2^ among the PLIC study cohort which were matched by age and gender with the NefroPLIC cohort. Baseline median filtration rate of the PLIC cohort was 67.51 (63.15--73.27) mL/min/1.73 m^2^, the cohort was followed for up to 84 months.

In this subset of the PLIC cohort, 1 μg/mL reduced LCAT concentration was predictive for 0.765 (0.325--1.205) mL/min reduction from basal eGFR (*p* = 0.001), when the linear regression model included age, gender, BMI, systolic and diastolic blood pressure, anti-hypertensive treatments, total cholesterol, triglycerides, HDL-c, lipid lowering drugs, glucose, oral glucose lowering drugs as co-variates ([Table S3a](#app1-jcm-09-02289){ref-type="app"}). Vice versa, per 1 mg/dL reduction of HDL-c a mean 0.005 (−0.043--0.033) reduction in eGFR was predicted (*p* = 0.787) ([Table S3b](#app1-jcm-09-02289){ref-type="app"}).

Of note, also in this subset of the PLIC cohort, HDL-c did not correlate with the LCAT concentration; when we divided this group into tertiles according to plasma LCAT concentration, HDL-c were 54.5 (48.0--67.2) in the 1st (low LCAT) vs. 55.0 (48.2--61.7) in 2nd vs. 59.0 (51.0--68.0) mg/dL in the third (high LCAT), *p* = 0.209). Vice versa, subjects in the lowest (1st) LCAT tertile showed higher plasma triglycerides vs. the others (96.5 (73.2--131.0 mg/dL vs. 98.0 (76.0--133.2) mg/dL of the second and vs. 84.0 (61.0--106.0) mg/dL of the third tertile, *p* = 0.039), they were taking more anti-hypertensive (35.2% vs. 32.14% the 2nd vs. 14.5% the third, *p* = 0.025) and oral glucose lowering treatments (16.7% vs. 3.6% vs. 1.8%, *p* = 0.004) ([Table 3](#jcm-09-02289-t003){ref-type="table"}). Thus, to verify whether reduced LCAT concentration is predictive for faster eGFR reduction beyond these patterns of metabolic alterations, we also divided the subset of the PLIC cohort in LCAT tertiles ([Table 3](#jcm-09-02289-t003){ref-type="table"}). When the annual eGFR reduction was plotted according to LCAT tertiles at baseline, subjects in the 1st tertile (mean plasma LCAT concentration of 3.89 μg/mL) showed a significantly faster progression of kidney impairment compared to subjects in the 3rd tertile (mean plasma LCAT concentration of 6.01 μg/mL) with a mean annual decline of eGFR of 2.096 (1.283--0.693) mL/min/year vs.0.693 (0.074--1.459) mL/min/year, even after adjusting for age, gender, systolic/diastolic blood pressure, anti-hypertensive treatments, glucose, oral glucose lowering therapies, total cholesterol, triglycerides, HDL-c and lipid lowering treatments ([Table 4](#jcm-09-02289-t004){ref-type="table"}).

3.3. Serum from Subjects with Low Plasma LCAT Concentration Mediates ROS Production in Renal Cells and rhLCAT Limits Serum Pro-Oxidative Effect {#sec3dot3-jcm-09-02289}
-----------------------------------------------------------------------------------------------------------------------------------------------

To test the hypothesis whether low plasma LCAT concentration can contribute to podocyte damage before the occurrence of changes of renal function, serum-mediated ROS production was tested in cultured podocytes and tubular cells. Serum was collected from a representative group of subjects from the subset of the PLIC cohort belonging to the 1st LCAT tertile (*n* = 11) and compared with serum obtained from subjects belonging to the 3rd LCAT tertile (*n* = 11) ([Table S4](#app1-jcm-09-02289){ref-type="app"}). Serum of subjects in 1st LCAT tertile promoted a significant increase in ROS production in podocytes compared to that observed with serum from subjects in the 3rd LCAT tertile ([Figure 2](#jcm-09-02289-f002){ref-type="fig"}a); this effect was independent of HDL-c levels (Spearman correlation *r* = −0.125, *p* = 0.615). A similar effect was observed when tubular cells were incubated with serum from subjects in 1st LCAT tertile or in 3rd LCAT tertile ([Figure 2](#jcm-09-02289-f002){ref-type="fig"}b). In addition, podocytes incubated with serum from subjects in 1st LCAT tertile had markedly reduced podocin expression compared to podocytes incubated with serum from subjects in the 3rd LCAT tertile (1st LCAT tertile 0.78 ± 0.19 vs. 3rd LCAT tertile 1.74 ± 0.56, *p* = 0.036), suggesting a reduction in podocyte functionality under low LCAT concentration conditions.

To prove that low LCAT concentration was responsible for the increased damaging effect of serum in renal cells, serum from subjects in the 1st LCAT tertile was incubated with rhLCAT \[[@B24-jcm-09-02289]\] to restore a concentration comparable to that of subjects in the 3rd tertile, thus allowing a proper HDL remodeling. Then, podocytes and tubular cells were incubated under these conditions ([Figure 2](#jcm-09-02289-f002){ref-type="fig"}). Interestingly, the addition of rhLCAT to sera from subjects in the 1st tertile reduced serum-mediated ROS production to a level similar to that observed with sera from 3rd LCAT tertile subjects in podocytes ([Figure 2](#jcm-09-02289-f002){ref-type="fig"}a) and, even more strikingly, in tubular cells ([Figure 2](#jcm-09-02289-f002){ref-type="fig"}b). The addition of serum-free rhLCAT to podocytes had a neutral effect on ROS production, thus suggesting that LCAT-induced modifications in lipoproteins, and specifically in HDL, may be responsible for the observed effect. Indeed, incubation of plasma with rhLCAT resulted, as expected, in a significant decrease in unesterified cholesterol and in a significant 50% reduction in the preβ-HDL particle content ([Table S5](#app1-jcm-09-02289){ref-type="app"}).

4. Discussion {#sec4-jcm-09-02289}
=============

The main finding of our study is that the reduced plasma LCAT concentration predicts CKD progression over time in patients with renal dysfunction, and, even more striking, it predicts the impairment of kidney function in the general population. This observation extends previous cross-sectional reports by us and others showing that low HDL-c levels are typically observed in CKD patients \[[@B6-jcm-09-02289],[@B8-jcm-09-02289]\], and that reduced LCAT concentration is a major determinant of the low HDL phenotype in CKD \[[@B7-jcm-09-02289]\].

LCAT is a key player in lipoprotein metabolism, being the only enzyme able to esterify cholesterol in plasma and other biological fluids. LCAT is predominantly synthesized by the liver and it circulates in plasma bound to HDL, and, to a lesser extent, to apoB-containing lipoproteins. LCAT plays a major role in HDL maturation and remodeling by esterifying the free cholesterol present in nascent discoidal HDL particles \[[@B25-jcm-09-02289]\]. Subjects with genetic LCAT deficiency present with largely immature and discoidal HDL \[[@B26-jcm-09-02289]\] and subjects with genetic LCAT deficiency accumulate in plasma largely immature and discoidal HDL \[[@B26-jcm-09-02289]\], large discoidal LDL particles, and the abnormal lipoprotein X \[[@B18-jcm-09-02289]\]. The major clinical complication observed in LCAT deficient subjects is kidney dysfunction; carriers often present with proteinuria very early in life \[[@B27-jcm-09-02289]\], and they usually develop renal failure with symptomatic edema and hypertension during the third-fourth decade of life \[[@B18-jcm-09-02289]\]. Plasma lipoprotein alterations have been related to renal disease \[[@B17-jcm-09-02289]\]; and, indeed, renal disease can reoccur in LCAT deficient cases who underwent kidney transplantation \[[@B28-jcm-09-02289]\], thus supporting the systemic cause of the renal damage.

We have previously shown that CKD patients have a partial secondary LCAT deficiency \[[@B7-jcm-09-02289]\], likely due to a down-regulation of hepatic LCAT gene expression \[[@B29-jcm-09-02289]\], which associates with abnormalities of the HDL phenotype similar to that observed in genetic LCAT deficiency. These abnormalities include low plasma HDL-c and apoA-I levels, a low level of particles containing apoA-I and apoA-II, and a high content of discoidal preβ-HDL \[[@B7-jcm-09-02289]\]. This peculiar profile is clearly related to the residual amount of circulating LCAT, as shown by the gene-dose dependent effect observed for these biomarkers in carriers of genetic LCAT deficiency \[[@B30-jcm-09-02289]\].

Of note, in our CKD patients, low HDL-c levels and reduced LCAT concentration independently predicted faster CKD progression. HDL-c and LCAT do not correlate in the present study, differently from what was observed in end stage renal disease patients \[[@B7-jcm-09-02289]\] but in agreement with the absence of correlation observed in the general population \[[@B31-jcm-09-02289]\]. The predictive value of the reduced LCAT concentration was unaffected by the presence of albuminuria, and when apoA-I was included in the model ([Table S6](#app1-jcm-09-02289){ref-type="app"}), a finding coupled with lack of correlation between LCAT and basal eGFR, blood urea nitrogen, albuminuria, or urinary-to-creatinine ratio. Besides, both low HDL-c and LCAT concentration predicted disease progression in diabetic CKD patients (97 out of 164 from the nefroPLIC cohort) and renal function worsening in non-diabetic subjects (153 out of 165 from the PLIC cohort) ([Table S7](#app1-jcm-09-02289){ref-type="app"}).

Taken together, the present findings highlight that the compromised plasma cholesterol esterification is relevant for CKD progression and renal function impairment even at initial stages of renal dysfunction. At the same time, these data call for the involvement of LCAT in the development of renal damage. We have shown that sera from subjects with low LCAT concentration, characterized by an increased unesterified/total cholesterol ratio and accumulation of discoidal preβ-HDL ([Table S4](#app1-jcm-09-02289){ref-type="app"}), present with pro-oxidative effects on podocytes and tubular cells and impair podocin expression that may contribute to the onset and progression of renal dysfunction observed later in these subjects \[[@B32-jcm-09-02289]\]. The causal relation between low LCAT concentration and increased serum-mediated ROS production was confirmed by the demonstration that in vitro addition to sera in the low LCAT group of a physiological amount of rhLCAT can correct HDL abnormalities associated with low LCAT levels, and it reduces serum-mediated ROS production in renal cells. Most importantly, LCAT protective and anti-oxidant functions are not exerted directly by the enzyme, but result from the modifications induced by the enzyme in plasma lipoproteins, and specifically on HDL particles. Transient LCAT overexpression was already shown to be associated with a reduction of oxidative stress in a mouse model characterized by impaired HDL antioxidant capacity \[[@B33-jcm-09-02289]\].

In conclusion, this is the first study that prospectively addresses the impact of plasma LCAT levels in predicting renal disease onset and progression. Our data demonstrate that reduced circulating LCAT levels predict CKD progression at early stages of renal dysfunction independent of changes in HDL-c levels, supporting the hypothesis that changes in HDL subclass distribution, besides HDL-c levels \[[@B6-jcm-09-02289]\] contribute to the progression of renal damage. Our in vitro data support the hypothesis that the pharmacological modulation of LCAT, either with the recombinant protein or with small molecule activators, can improve the abnormal HDL phenotype in CKD, thus reducing serum pro-oxidative effects associated with low LCAT. Whether LCAT modulation could also restore the defective functionality of CKD HDL \[[@B12-jcm-09-02289],[@B34-jcm-09-02289],[@B35-jcm-09-02289]\], thus contributing to an amelioration of the cardiovascular profile of CKD patients, remains to be determined and should be tested in future studies.

The following are available online at <https://www.mdpi.com/2077-0383/9/7/2289/s1>. Table S1: Reduced HDL-c predicts faster CKD progression, but dependently from reduced LCAT concentration, Table S2: Reduced LCAT concentration specifically predicts risk of dialysis entry and/or creatinine doubling and all-cause mortality, Table S3: Reduced LCAT concentration predicts higer annual eGFR reduction more significantly than reduced HDL-c, Table S4: Characteristics of subjects enrolled in the in vitro studies, Table S5: Lipid levels after incubation of plasma with or without rhLCAT, Table S6: Reduced LCAT concentration predicts faster CKD progression independently from ApoA-I circulating levels, Table S7: Predictive value of reduced HDL-c and reduced LCAT concentration for CKD progression and renal function impairment in patients with and without diabetes.
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![Low plasma lecithin:cholesterol acyltransferase (LCAT) concentration predicts fast chronic kidney disease (CKD) progression over time. (**a**) Differences in plasma LCAT concentration in CKD patients divided according to fast or slow CKD progression. CKD progression was defined as entry in dialysis and/or doubling of creatinine levels. *p* = 0.002 is derived from the non-parametric comparison test; data are presented as box-plots reporting median and 10th--90th percentile around the median. (**b**--**g**) Kaplan--Meier survival analyses showing an cumulative event rate in the CKD cohort divided by LCAT tertiles (1st low; 3rd high) for (**b**) dialysis entry and/or creatinine plasma levels doubling, (**c**) all-cause mortality, (**d**) cardiovascular fatal or non-fatal events, (**e**) composite outcome of dialysis entry and/or creatinine doubling and all-cause mortality, (**f**) composite outcome of dialysis entry and/or creatinine doubling and cardiovascular fatal or non-fatal events, (**g**) composite outcome of dialysis entry and/or creatinine doubling, cardiovascular fatal or non-fatal events, all-cause mortality. *p*-values are derived from log-rank test.](jcm-09-02289-g001){#jcm-09-02289-f001}

![ROS production in renal cells. Box-plots showing the difference of reactive oxygen species (ROS) production after incubation with serum from subjects from the 1st and 3rd lecithin:cholesterol acyltransferase (LCAT) tertiles and with serum from subjects in 1st LCAT tertile incubated with recombinant human LCAT (rhLCAT) in (**a**) podocytes and in (**b**) tubular cells. Data are presented as box-plots reporting median and 10th--90th percentile around the median. *p*-values are derived from the Kruskall--Wallis test for comparison between each group. ROS are represented as fold versus untreated cells; the detected fluorescence was corrected for total protein and expressed as fold versus fluorescence corrected for protein content in cells not incubated with serum.](jcm-09-02289-g002){#jcm-09-02289-f002}
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###### 

Clinical and biochemical characteristics of the CKD cohort.

                                                               Entire CKD Cohort       Slow CKD Progression   Fast CKD Progression      *p*
  ------------------------------------------------------------ ----------------------- ---------------------- ------------------------- ---------
  *N*                                                          164                     132                    32                        
  Age (years)                                                  68 (61--75)             68 (59--74)            73 (66--79)               \<0.001
  Gender (men, *n* (%))                                        107 (65.2)              86 (65.1)              21 (65.6)                 0.957
  BMI (kg/m^2^)                                                29.44 (5.46)            29.64 (5.55)           28.67 (5.24)              0.589
  Waist/hip                                                    0.970 (0.071)           0.969 (0.069)          0.974 (0.083)             0.568
  Systolic Blood Pressure (mmHg)                               144 (18)                144 (18)               144 (21)                  0.418
  Diastolic Blood Pressure (mmHg)                              83 (12)                 83 (10)                84 (18)                   0.283
  ACE Inhibitors (*n* (%), yes)                                77 (46.9)               63 (47.7)              14 (43.7)                 0.976
  ARBs (*n* (%), yes)                                          54 (32.9)               43 (32.6)              11 (34.4)                 0.609
  ACE Inhibitors + ARBs Association (*n* (%), yes)             31 (18.9)               23 (17.4)              8 (25.0)                  0.326
  Diuretics (*n* (%), yes)                                     59 (35.9)               46 (34.8)              13 (40.6)                 0.383
  Diuretics + ARBs Association (*n* (%), yes)                  28 (17.1)               21 (15.9)              7 (21.8)                  0.421
  Beta-Blockers (*n* (%), yes)                                 30 (18.3)               28 (21.2)              2 (6.2)                   0.064
  C-Reactive Protein (mg/L)                                    0.23 (0.12--0.45)       0.37 (0.12--0.41)      0.43 (0.18--0.51)         0.149
  Fasting Glucose Levels (mg/dL)                               126.5 (100.0--157.5)    132.0 (103.0--165.0)   112.5 (94.0--147.0)       0.044
  Glycated Hemoglobin (%)                                      6.6 (6.1--7.4)          6.8 (6.2--7.4)         6.2 (6.0--6.9)            0.104
  OGLT (*n* (%), yes)                                          70 (42.7)               60 (45.4)              10 (31.2)                 0.145
  OGLT Vintage Before Basal Evaluation (months)                84 (36--180)            84 (36--180)           120 (31--168)             0.952
  Insulin Analogues (*n* (%), yes)                             27 (16.4)               23 (17.4)              4 (12.5)                  0.500
  Insulin Analogues Vintage Before Basal Evaluation (months)   24 (12--120)            24 (12--120)           48 (7--108)               0.846
  Creatinine (mg/dL)                                           1.52 (1.00--2.02)       1.30 (0.90--1.80)      2.77 (1.8--4.1)           \<0.001
  eGFR (mL/min/1.73 m^2^)                                      44.65 (30.00--68.46)    49.42 (35.06--71.23)   19.55 (16.01--35.63)      \<0.01
  Urinary Creatinine/Albumin (mg/g)                            6.68 (1.74--36.14)      5.55 (1.56--26.61)     39.93 (2.74--276.73)      0.004
  Urinary Albumin (mg/L)                                       33.66 (10.30--228.33)   28.06 (9.85--174.85)   434.53 (47.80--1049.55)   0.001
  Blood Urea Nitrogen (mg/dL)                                  52.00 (40.00--82.00)    49.85 (38.02--69.52)   98.50 (61.67--127.77)     \<0.001
  Calcium (mmol/L)                                             2.36 (2.30--2.44)       2.36 (2.30--2.44)      2.35 (2.24--2.43)         0.543
  Phosphorous (mmol/L)                                         1.09 (0.94--1.20)       1.05 (0.94--1.18)      1.21 (1.05--1.33)         0.005
  Total Cholesterol (mg/dL)                                    201.5 (46.2)            197.2 (43.4)           217.8 (54.8)              0.133
  Triglycerides (mg/dL)                                        136.0 (88.0--187.0)     128.0 (87.2--182.0)    143.5 (101.7--223.0)      0.061
  LDL-Cholesterol (mg/dL)                                      120.9 (42.0)            116.6 (38.7)           136.3 (51.2)              0.086
  HDL-Cholesterol (mg/dL)                                      50.40 (15.22)           51.94 (14.60)          44.40 (15.07)             0.010
  Non-HDL-Cholesterol (mg/dL)                                  151.1 (46.8)            145.2 (43.5)           173.4 (53.9)              0.013
  Apolipoprotein A-I (mg/dL)                                   147.0 (131.0--164.0)    148.0 (132.0--166.0)   143.5 (121.5--152.7)      0.043
  Apolipoprotein B (mg/dL)                                     127.0 (111.0--146.0)    126.0 (111.0--142.0)   130.5 (114.2--169.5)      0.385
  Hypolipidemic Treatments, Statins (*n*, yes)                 57 (34.5)               50 (37.8)              7 (21.8)                  0.152
  Hypolipidemic Treatments, Fibrates (*n*, yes)                7 (4.2)                 5 (3.7)                2 (6.2)                   0.484
  Anti-Platelets (ASA) (*n*, yes)                              64 (39.0)               54 (40.9)              10 (31.2)                 0.444

Data are reported as mean (SD) or median (Interquartile Range, as the range between the 25th and the 75th percentile around each median value). *p*-values indicate differences between the two chronic kidney disease (CKD) groups. "ARBs": angiotensin receptor blockers; ''ASA'': acetilsalycilic acid or other anti-platelets; "OLGT": Oral glucose lowering treatments; ''BMI'': body mass index; ''ACE'': angiotensin-converting enzyme; ''eGFR'': estimated glomerular filtration rate; ''LDL'': low density lipoprotein; ''HDL'': high-density lipoprotein.
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###### 

Clinical and biochemical characteristics of the CKD cohort per LCAT tertiles.

                                                               LCAT Tertiles                                                          
  ------------------------------------------------------------ ----------------------- ----------------------- ---------------------- -------
  Age (years)                                                  68 (62--71)             70 (64--75)             66 (58--75)            0.232
  Gender (men, *n* (%))                                        39 (72.2)               34 (61.3)               34 (61.3)              0.421
  BMI (kg/m^2^)                                                29.22 (25.68--33.36)    27.91 (24.87--32.23)    27.88 (25.71--32.38)   0.480
  Waist/hip                                                    0.97 (0.07)             0.95 (0.07)             0.98 (0.07)            0.275
  Systolic Blood Pressure (mmHg)                               145 (131--160)          140 (130--155)          140 (130--160)         0.620
  Diastolic Blood Pressure (mmHg)                              80 (80--90)             80 (80--90)             85 (80--90)            0.266
  ACE Inhibitors (*n* (%), yes)                                24 (44.4)               26 (47.3)               27 (49.1)              0.973
  ARBs (*n* (%), yes)                                          14 (25.9)               19 (34.5)               21 (38.2)              0.495
  ACE Inhibitors + ARBs Association (*n* (%), yes)             8 (14.8)                10 (18.1)               13 (23.6)              0.518
  Diuretics (*n* (%), yes)                                     18 (33.3)               22 (40)                 19 (34.5)              0.815
  Diuretics + ARBs Association (*n* (%), yes)                  7 (13.0)                10 (18.1)               11 (20.0)              0.627
  Beta-Blockers (*n* (%), yes)                                 6 (11.1)                12 (21.8)               12 (21.8)              0.313
  C-Reactive Protein (mg/L)                                    0.26 (0.15--0.50)       0.28 (0.10--0.49)       0.19 (0.11--0.40)      0.341
  Fasting Glucose Levels (mg/dL)                               135.5 (101.0--174.5)    123.0 (102.0--159.0)    123.0 (99.0--154.0)    0.777
  Glycated Hemoglobin (%)                                      6.55 (6.10--7.47)       6.60 (6.00--7.40)       7.00 (6.30--7.55)      0.324
  OGLT (*n* (%), yes)                                          20 (37.1)               26 (47.2)               24 (43.6)              0.549
  OGLT Vintage (Months Before Basal Evaluation)                72 (36--174)            78 (36--210)            90 (27--180)           0.666
  Insulin Analogues (*n* (%), yes)                             6 (11.1)                14 (25.4)               7 (12.7)               0.086
  Insulin Analogues Vintage (Months Before Basal Evaluation)   60 (9--120)             24 (12--120)            48 (11--156)           0.849
  Creatinine (mg/dL)                                           1.63 (1.09--2.13)       1.16 (0.90--1.90)       1.61 (1.10--1.85)      0.238
  eGFR (mL/min/1.73 m^2^)                                      47.56 (25.43--48.91)    44.49 (32.82--73.67)    42.24 (29.73--59.36)   0.738
  Urinary Creatinine/Albumin (mg/g)                            6.14 (2.24--73.90)      8.57 (1.62--28.91)      5.45 (1.21--37.11)     0.663
  Urinary Albumin (mg/L)                                       30.80 (12.50--316.20)   39.43 (10.27--203.00)   32.90 (9.44--225.63)   0.890
  Blood Urea Nitrogen (mg/dL)                                  52.0 (40.5--85.7)       50.9 (37.1--70.8)       56.5 (44.9--86.3)      0.477
  Calcium (mmol/L)                                             2.37 (2.33--2.44)       2.34 (2.27--2.44)       2.37 (2.30--2.43)      0.401
  Phosphorous (mmol/L)                                         1.12 (0.18)             1.05 (0.18)             1.06 (0.18)            0.178
  Total Cholesterol (mg/dL)                                    204.6 (50.3)            200.6 (41.2)            198.4 (47.4)           0.512
  Triglycerides (mg/dL)                                        140.0 (93.2--189.2)     122.0 (88.0--183.0)     143.0 (88.0--176.0)    0.723
  LDL-Cholesterol (mg/dL)                                      123.1 (45.7)            120.7 (36.1)            117.4 (44.3)           0.487
  HDL-Cholesterol (mg/dL)                                      46.0 (37.0--61.0)       49.0 (42.0--60.0)       48.0 (42.0--57.0)      0.469
  Non-HDL-cholesterol (mg/dL)                                  161.0 (120.7--185.5)    147.0 (119.0--175.0)    142.0 (119.0--167.0)   0.436
  Apolipoprotein A-I (mg/dL)                                   146.8 (32.1)            148.8 (27.4)            151.9 (29.7)           0.893
  Apolipoprotein B (mg/dL)                                     130.6 (33.1)            129.8 (28.6)            132.02 (32.5)          0.999
  Hypolipidemic Treatments, Statins (*n*, yes)                 19 (35.2)               14 (25.4)               24 (43.6)              0.132
  Hypolipidemic Treatments, Fibrates (*n*, yes)                1 (1.8)                 5 (9.1)                 1 (1.8)                0.104
  Anti-Platelets (ASA) (*n*, yes)                              23 (42.6)               22 (40.0)               19 (34.5)              0.547

Data are reported as mean (SD) or median (interquartile range, as the range between the 25th and the 75th percentile around each median value). "ARBs": angiotensin receptor blockers; ''ASA": acetilsalycilic acid or other anti-platelets; "OLGT": oral glucose lowering treatments; ''BMI'': body mass index; ''ACE'': angiotensin-converting enzyme; ''eGFR'': estimated glomerular filtration rate; ''LDL'': low-density lipoprotein; ''HDL'': high-density lipoprotein; ''CKD'': chronic kidney disease; ''LCAT'': lecithin:cholesterol acyltransferase.
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###### 

Clinical and biochemical characteristics of the PLIC cohort at basal visit per LCAT tertiles.

  LCAT (μg/mL) (Mean (Range))                     Entire Cohort                                 LCAT Tertiles                                      
  ----------------------------------------------- ---------------------- ---------------------- ---------------------- --------------------------- -------
  Age (years)                                     68 (66--72)            69 (66--73)            67 (65--72)            69 (66--72)                 0.742
  Gender (men, *n* (%))                                                  26 (48.1)              27 (48.2)              27 (49.1)                   0.994
  BMI (kg/m^2^)                                   26.31 (24.53--28.70)   26.49 (24.37--29.15)   25.85 (24.16--29.25)   26.33 (24.86--28.07)        0.949
  Waist/hip                                       0.89 (0.07)            0.89 (0.07)            0.90 (0.08)            0.89 (0.07)                 0.826
  Systolic Blood Pressure (mmHg)                  135 (120--150)         135 (120--149)         132 (120--150)         140 (120--150)              0.860
  Diastolic Blood Pressure (mmHg)                 80 (75--80)            80 (76--80)            80 (75--80)            80 (70--80)                 0.431
  Anti-Hypertensive Treatments (*n* (%), yes)     45 (27.3)              19 (35.2)              18 (32.14)             8 (14.5)                    0.025
  C-Reactive Protein (mg/L)                       0.19 (0.08--0.39)      0.16 (0.04--0.32)      0.19 (0.09--0.38)      0.20 (0.07--0.41)           0.592
  Fasting Glucose Levels (mg/dL)                  98.0 (90.0--107.0)     99.0 (90.0--110.2)     96.0 (91.0--104.0)     97.0 (90.0--109.0)          0.614
  OGLT (*n* (%), yes)                             12 (7.3)               9 (16.7)               2 (3.6)                1 (1.8)                     0.004
  OGLT Vintage (Months Before Basal Evaluation)   32(24--80)             24 (22--56)            80; 80 ∗               80                          0.051
  Creatinine (mg/dL)                              0.91 (0.80--1.03)      0.92 (0.79--1.00)      0.89 (0.79--1.02)      0.96 (0.80--1.08)           0.418
  eGFR (mL/min/1.73 m^2^)                         67.51 (63.15--73.27)   68.71 (63.78--74.67)   68.14 (63.74--74.36)   66.52 (62.02--72.05)        0.178
  Total Cholesterol (mg/dL)                       232.8 (44.94)          223.4 (48.7)           237.2 (45.9)           237.8 (38.8)                0.112
  Triglycerides (mg/dL)                           95.5 (69.2--123.7)     96.5 (73.2--131.0)     98.0 (76.0--133.2)     84.0 (61.0--106.0) \*^,†^   0.039
  LDL-Cholesterol (mg/dL)                         153.0 (41.4)           142.0 (42.9)           157.5 (43.0)           158.9 (36.1)                0.080
  HDL-Cholesterol (mg/dL)                         56.0 (49.0--65.7)      54.5 (48.0--67.2)      55.0 (48.2--61.7)      59.0 (51.0--68.0)           0.209
  Non-HDL-Cholesterol (mg/dL)                     173.0 (142.2--206.0)   166.0 (134.5--189.2)   180.0 (144.0--213.0)   176.0 (146.0--204.0)        0.133
  Apolipoprotein A-I (mg/dL)                      153.3 (22.7)           152.3 (21.9)           151.0 (23.9)           157.7 (21.1)                0.160
  Apolipoprotein B (mg/dL)                        123.1 (35.36)          115.4 (37.3)           126.6 (36.9)           127.4 (31.0)                0.111
  Hypolipidemic Treatments, Statins (*n*, yes)    53 (32.2)              15 (27.8)              19 (33.9)              19 (34.5)                   0.717
  Anti-Platelets (ASA) (*n*, yes)                 34 (20.6)              12 (22.2)              12 (21.4)              10 (18.2)                   0.937

Data are reported as mean (SD) or median (Interquartile Range, as the range between the 25th and the 75th percentile around each median value). \* *p* \< 0.05 vs. 1st LCAT tertile; ^†^ *p* \< 0.05 vs. 2nd LCAT tertile; ∗ raw data for *n* = 2 subjects are reported. ''ASA ": Acetilsalycilic Acid or other anti-platelets; ''OLGT": oral glucose lowering treatments; ''BMI'': body mass index; ''ACE'': angiotensin-converting enzyme; ''eGFR'': estimated glomerular filtration rate; ''LDL'': low-density lipoprotein; ''HDL'': high-density lipoprotein; ''LCAT'': lecithin:cholesterol acyltransferase.
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###### 

Annual eGFR reduction per LCAT tertiles.

  ---------------------------------------------------------------------------------------------
  Model   1st Tertile                2nd Tertile                3rd Tertile
  ------- -------------------------- -------------------------- -------------------------------
  1       −2.249 (−1.524-- −2.974)   −1.273 (−0.562-- −1.985)   −0.533 (−0.186-- −1.251)\
                                                                (*p* = 0.018 vs. 1st tertile)

  2       −2.260 (−1.550-- −2.969)   −1.279 (−0.582-- −1.976)   −0.516 (−0.187-- −1.220)\
                                                                (*p* = 0.014 vs. 1st tertile)

  3       −2.015 (−1.278-- −2.752)   −1.344 (−0.645-- −2.042)   −0.684 (−0.043-- −1.411)\
                                                                (*p* = 0.001 vs. 1st tertile)

  4       −2.096 (−1.283-- −2.908)   −1.260 (−0.522-- −1.998)   −0.693 (−0.074-- −1.459)\
                                                                *p* = 0.001 vs. 1st tertile
  ---------------------------------------------------------------------------------------------

Data are reported as mean (lower and upper bound around the mean value) of annual estimated glomerular filtration rate (eGFR) reduction. *p-*values are derived from ANCOVA (Bonferroni post-hoc) with Model 1: unadjusted; Model 2: adjusting for age and gender; Model 3: adjusting for age, gender, body mass index (BMI), systolic and diastolic blood pressure, glucose, total cholesterol, triglycerides, high-density lipoprotein-cholesterol (HDL-c); Model 4: adjusting for age, gender, BMI, systolic and diastolic blood pressure, anti-hypertensive treatments, glucose, oral glucose lowering treatments, total cholesterol, triglycerides, HDL-c, hypolipideamic treatments. ''LCAT'': lecithin:cholesterol acyltransferase.

[^1]: Contributed equally as first authors.
